Logo Image
|Videos|March 12, 2021

Practical Steps to Mitigating Health Iniquity

Episodes in this series
References
1. Filippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4(1):43.
doi: 10.1038/s41572-018-0041-4
2. Who gets MS? (Epidemiology). National Multiple Sclerosis Society website. Accessed December 22, 2020. https://www.nationalmssociety.org/What-is-MS/Who-Gets-MS
3. Yalachkov Y, Soydaş D, Bergmann J, et al. Determinants of quality of life in relapsing-remitting and progressive multiple sclerosis. Mult Scler Relat Disord. 2019;30:33-37. doi: 10.1016/j.msard.2019.01.049
4. Coyle P, Robinson J, Schobel V. Initial multiple sclerosis DMT recommendation: impact of comorbidities and prognostic profile in the United States. Presented at: ECTRIMS 2019. September 11-13, 2019; Stockholm, Sweden. Abstract P1351.
5. Jaworski M, Wijcik C, Youngs M, et al. Employment outcomes in multiple sclerosis. Presented at: MSVirtual2020: 8th ACTRIMS-ECTRIMS Meeting; September 11-13, 2020. Presentation P1026.
6. Ziemssen T, Derfuss T, de Stefano N, et al. Optimizing treatment success in multiple sclerosis.
J Neurol. 2016;263(6):1053-1065. doi: 10.1007/s00415-015-7986-y
7. Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ. 2013;16(5):639-647.
doi: 10.3111/13696998.2013.778268
8. Anderson SS, Philbrick AM. Improving multiple sclerosis care: an analysis of the necessity for medication therapy management services among the patient population. J Manag Care Spec Pharm. 2014;20(3):254-261. doi: 10.18553/jmcp.2014.20.3.254
9. Fabius CD, Thomas, KS, Zhang T, Ogarek J, Shireman TI. Racial disparities in Medicaid home and community-based service utilization and expenditures among person with multiple sclerosis. BMC Health Serv Res. 2018;18(1):773. doi: 10.1186/s12913-018-3584-x
10. Khan O, Williams MJ, Amezcua L, Javed A, Larsen KE, Smrtka JM. Multiple sclerosis in US minority populations. Neurology: Clinical Practice. 2015;5(2):132-142. doi: 10.1212/CPJ.0000000000000112
11. Romanelli RJ, Huang Q, Lacy J, et al. Multiple sclerosis in a multi-ethnic population from Northern California: a retrospective analysis, 2010–2016. BMC Neurol. 2020;20(163). https://doi.org/10.1186/s12883-020-01749-6
12. African Americans. National Multiple Sclerosis Society website. Accessed December 20, 2020. https://www.nationalmssociety.org/What-is-MS/Who-Gets-MS/African-American-Resources
13. Naismith RT, Trinkaus K, Cross AH. Phenotype and prognosis in African-Americans with multiple sclerosis: a retrospective chart review. Mult Scler. 2006;12(6):775-781. doi: 10.1177/1352458506070923
14. The use of disease-modifying therapies in multiple sclerosis: Principles and current evidence. A consensus paper by the Multiple Sclerosis Coalition. National Multiple Sclerosis Society website. Published July 2014. Updated September 2019. https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/DMT_Consensus_MS_Coalition.pdf
15. Amezcua L, Oksenberg JR, McCauley JL. MS in self-identified Hispanic/Latino individuals living in the US. Mult Scler J Exp Transl Clin. 2017;3(3):2055217317725103. doi: 10.1177/2055217317725103
16. Ventura RE, Antezana AO, Bacon T, Kister I. Hispanic Americans and African Americans with multiple sclerosis have more severe disease course than Caucasian Americans. Mult Scler. 2017;23(11):1554-1557. doi: 10.1177/1352458516679894
17. Buchanan RJ, Zuniga MA, Carrillo-Zuniga G, et al. Comparisons of Latinos, African Americans, and Caucasians with multiple sclerosis. Ethn Dis. 2010;20(4):451-457.
18. Minden SL, Hoaglin DC, Hadden L, Frankel D, Robbins T, Perloff J. Access to and utilization of neurologists by people with multiple sclerosis. Neurology. 2008;70(13 Pt 2):1141-1149. doi: 10.1212/01.wnl.0000306411.46934.ef
19. Livingston T, Fay M, Iyer R, Wells W, Pill MW. Quantifying differences in health care consumption for the management of multiple sclerosis within privately and publicly insured health care programs.
J Manag Care Spec Pharm. 2016;22(12):1385-1391. doi: 10.18553/jmcp.2016.22.12.1385
20. Chambers JD, Anderson JE, Wilkinson CL, Pallavi R. Variation in the coverage of disease-modifying multiple sclerosis drugs among US payers. Am J Pharm Benefits. 2017;9(5):155-159. https://doi.org/10.18553/jmcp.2016.22.10.1176
21. Bourdette DN, Hartung DM, Whitham RH. Practices of US health insurance companies concerning MS therapies interfere with shared decision-making and harm patients. Neurol Clin Pract. 2016;6(2):177-182. doi:10.1212/CPJ.0000000000000208
22. Cree BA, Al-Sabbagh A, Bennett R, Goodin D. Response to interferon beta-1a treatment in African American multiple sclerosis patients. Arch Neurol. 2005;62(11):1681-1683. doi: 10.1001/archneur.62.11.1681

Related to this article

View more
8 takeaways from the MHE and Drug Topics post-midterms webinar
8 takeaways from the MHE and Drug Topics post-midterms webinar
Expect Democrats to flex their oversight powers even if President Donald Trump’s veto power blocks their efforts to reverse Medicaid cuts or restore enhanced ACA subsidies. The administration’s most-favored-nation policies and HHS Secretary Kennedy will probably be in the hot seat.
Read more